etalpha 0,5 mikrogram kapsler, bløde
cheplapharm arzneimittel gmbh - alfacalcidol - kapsler, bløde - 0,5 mikrogram
etalpha 0,5 mikrogram kapsler, bløde
2care4 aps - alfacalcidol - kapsler, bløde - 0,5 mikrogram
etalpha 1 mikrogram kapsler, bløde
cheplapharm arzneimittel gmbh - alfacalcidol - kapsler, bløde - 1 mikrogram
etalpha 2 mikrogram/ml orale dråber, opløsning
cheplapharm arzneimittel gmbh - alfacalcidol - orale dråber, opløsning - 2 mikrogram/ml
one-alpha 1 mikrogram kapsler, bløde
2care4 aps - alfacalcidol - kapsler, bløde - 1 mikrogram
etalpha 2 mikrogram/ml injektionsvæske, opløsning
orifarm a/s - alfacalcidol - injektionsvæske, opløsning - 2 mikrogram/ml
etalpha 0,25 mikrogram kapsler, bløde
2care4 aps - alfacalcidol - kapsler, bløde - 0,25 mikrogram
one-alpha 2 mikrogram/ml orale dråber, opløsning
2care4 aps - alfacalcidol - orale dråber, opløsning - 2 mikrogram/ml
crysvita
kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - narkotika til behandling af knoglesygdomme - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.
magnesia "dak" 500 mg filmovertrukne tabletter
orifarm healthcare a/s - magnesiumhydroxid - filmovertrukne tabletter - 500 mg